Evidence map›Paper›PMID 27056179›Full record

Trial reportRadiation oncology (London, England)2016

Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study.

Sophie Jacob, Atul Pathak, Denis Franck, Igor Latorzeff, Gaelle Jimenez, Olivier Fondard, Matthieu Lapeyre, Daniel Colombier, Eric Bruguiere, Olivier Lairez and 10 more

2 registry-linked trialsOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Radiation oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02605512 nacompletednot on this map

Early Detection and Prediction of Cardiotoxicity in Radiotherapy-treated Breast Cancer Patients

TypeinterventionalSponsorSophie JACOBRan2015 to 2020Enrolled118ConditionsBreast Cancer, Cardiac ToxicityArmsSubclinical cardiac lesions and biomarkers
NCT05454553 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Efficacity of Deep Inspiration Breath Hold and Intensity-modulated Radiotherapy in Preventing PErfusion Defect for Left Sided Breast Cancer (EDIPE)

TypeinterventionalSponsorInstitut de cancérologie Strasbourg EuropeRan2022 to 2024Enrolled58ConditionsBreast CancerArmsmyocardial perfusion SPECT
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Sophie JacobInstitut de Radioprotection et de Sureté Nucléaire (IRSN), PRP-HOM, SRBE, LEPID, Fontenay-aux-Roses, France. sophie.jacob@irsn.fr.
Atul PathakClinique Pasteur, Unité d'Hypertension artérielle, facteurs de risque et insuffisance cardiaque, Toulouse, France.
Denis FranckClinique Pasteur, Radiothérapie (Oncorad), Toulouse, France.
Igor LatorzeffClinique Pasteur, Radiothérapie (Oncorad), Toulouse, France.
Gaelle JimenezClinique Pasteur, Radiothérapie (Oncorad), Toulouse, France.
Olivier FondardClinique Pasteur, Cardiologie générale et interventionnelle, Toulouse, France.
Matthieu LapeyreClinique Pasteur, Radiologie, Toulouse, France.
Daniel ColombierClinique Pasteur, Radiologie, Toulouse, France.
Eric BruguiereClinique Pasteur, Radiologie, Toulouse, France.
Olivier LairezUniversity Hospital Rangueil, Cardiologie B, Toulouse, France.
Benoit FontenelClinique Pasteur, Laboratoire d'analyse, Toulouse, France.
Fabien MilliatInstitut de Radioprotection et de Sureté Nucléaire (IRSN), PRP-HOM, SRBE, L3R, Fontenay-aux-Roses, France.
Radia TamaratInstitut de Radioprotection et de Sureté Nucléaire (IRSN), PRP-HOM, SRBE, LR2I, Fontenay-aux-Roses, France.
David BroggioInstitut de Radioprotection et de Sureté Nucléaire (IRSN), PRP-HOM/SDI/LEDI, Fontenay-aux-Roses, France.
Sylvie DerreumauxInstitut de Radioprotection et de Sureté Nucléaire (IRSN), PRP-HOM, SER, UEM, Fontenay-aux-Roses, France.
Marianne DucassouClinique Pasteur, Radiothérapie (Oncorad), Toulouse, France.
Jean FerrièresINSERM, University Paul Sabatier, UMR1027, Epidemiology of cardiovascular diseases, Toulouse, France.
Dominique LaurierInstitut de Radioprotection et de Sureté Nucléaire (IRSN), PRP-HOM, SRBE, LEPID, Fontenay-aux-Roses, France.
Marc BenderitterInstitut de Radioprotection et de Sureté Nucléaire (IRSN), PRP-HOM, SRBE, Fontenay-aux-Roses, France.
Marie-Odile BernierInstitut de Radioprotection et de Sureté Nucléaire (IRSN), PRP-HOM, SRBE, LEPID, Fontenay-aux-Roses, France.
Clinique Pasteur · FRInstitut de Radioprotection et de Sûreté Nucléaire · FRHôpital Rangueil · FRLaboratoire de Recherche sur la Croissance Cellulaire, la Réparation et la Régénération Tissulaires · FRService de la Santé Publique · CHUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiotherapy (RT) for breast cancer presents a benefit in terms of reducing local recurrence and deaths resulting from breast cancer but it can lead to secondary effects due to the presence of neighboring cardiac normal tissues within the irradiation field. Breast RT has been shown to be associated with long-term increased risk of heart failure, coronary artery disease, myocardial infarction and finally cardiovascular death more than 10 years after RT. However, there is still a lack of knowledge for early cardiotoxicity induced by breast RT that can appear long before the onset of clinically significant cardiac events. Based on a 2-year follow-up prospective cohort of patients treated with breast RT, the BACCARAT (BreAst Cancer and CArdiotoxicity Induced by RAdioTherapy) study aims to enhance knowledge on detection and prediction of early subclinical cardiac dysfunction and lesions induced by breast RT and on biological mechanisms potentially involved, based on functional and anatomical cardiac imaging combined with simultaneous assessment of multiple circulating biomarkers and accurate heart dosimetry. METHODS/

designBACCARAT study consists in a monocentric prospective cohort study that will finally include 120 women treated with adjuvant 3D CRT for breast cancer, and followed for 2 years after RT. Women aged 50 to 70 years, treated for breast cancer and for whom adjuvant 3D CRT is indicated, without chemotherapy are eligible for the study. Baseline (before RT) and follow-up data include measurements of functional myocardial dysfunction including strain and strain rate based on 2D-speckle tracking echocardiography, anatomical coronary lesions including description of plaques in segments of coronary arteries based on Coronary computed tomography angiography, and a wide panel of circulating biomarkers. The absorbed dose is evaluated for the whole heart and its substructures, in particular the coronary arteries. Analysis on occurrence and evolution of subclinical cardiac lesions and biomarkers will be performed and completed with dose-response relationship. Multivariate model of normal tissue complication probability (NTCP) will also be proposed. DISCUSSION: Tools and results developed in the BACCARAT study should allow improving prediction and prevention of potential lesions to cardiac normal tissues surrounding tumors and ultimately enhance patients' care and quality of life.

trial registrationClinicalTrials.gov: NCT02605512.

Indexed as

AgedBiomarkersBreast NeoplasmsCardiotoxicityCoronary VesselsEchocardiographyFemaleFollow-Up StudiesHeartHeart DiseasesHumansMiddle AgedNeoplasm Recurrence, LocalPhenotypeProspective StudiesQuality of LifeBiomarkersBiomarkersBreast cancerCardiac toxicityFunctional and anatomical cardiac imagingHeart dosimetryRadiotherapy

Identifiers

PMID27056179
PMCPMC4823906
OpenAlexW2329506780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.